Laurence Marton Biography and Net Worth

Director of RenovoRx

Dr. Marton serves as a consultant to industry and to nonprofit, government, and academic institutions. In the nonprofit sector, Dr. Marton is an Emeritus Member of the Board of Trustees of the American Association for Cancer Research Foundation and is on the Board of Directors of Cancer Commons. In the for-profit sector, he serves on the Boards of Directors of Cellsonics, Matternet, Microsonic Systems, Nanotics, Omniox (also serving as Executive Chair), RenovoRx, and xCures and is an advisor to Assurance Health Data, PharmaJet, and the Precision Medicine World Conference.

Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine.

What is Laurence Marton's net worth?: The estimated net worth of Laurence Marton is at least $108.73 thousand as of April 8th, 2025. Marton owns 45,684 shares of RenovoRx stock worth more than $108,728 as of September 2nd. This net worth evaluation does not reflect any other assets that Marton may own. Learn More about Laurence Marton's net worth.
How do I contact Laurence Marton?: The corporate mailing address for Marton and other RenovoRx executives is 333 W. SANTA CLARA STREET SUITE 900, SAN JOSE CA, 95110. RenovoRx can also be reached via phone at 650-284-4433 and via email at [email protected]. Learn More on Laurence Marton's contact information.
Has Laurence Marton been buying or selling shares of RenovoRx?: Laurence Marton has not been actively trading shares of RenovoRx within the last three months. Most recently, on Tuesday, April 8th, Laurence Marton bought 12,050 shares of RenovoRx stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $10,242.50. Following the completion of the transaction, the director now directly owns 45,684 shares of the company's stock, valued at $38,831.40. Learn More on Laurence Marton's trading history.
Are insiders buying or selling shares of RenovoRx?: In the last year, RenovoRx insiders bought shares 9 times. They purchased a total of 94,000 shares worth more than $79,993.85. The most recent insider tranaction occured on May, 19th when CFO Mark Voll bought 25,000 shares worth more than $19,750.00. Insiders at RenovoRx own 9.4% of the company. Learn More about insider trades at RenovoRx.
Information on this page was last updated on 5/19/2026.

Laurence Marton Insider Trading History at RenovoRx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/8/2025	Buy	12,050	$0.85	$10,242.50	45,684

Laurence Marton Buying and Selling Activity at RenovoRx

RenovoRx Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Today's Range

Now: $2.42

$2.14

$2.48

50 Day Range

MA: $1.10

$0.85

$2.11

2 Week Range

Now: $2.42

$0.70

$2.48

Volume

1,418,723 shs

Average Volume

381,950 shs

Market Capitalization

$108.99 million

P/E Ratio

N/A

Dividend Yield